Prot #N91115-2CF-05 (SNO-6): A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with l

Project: Research project

Project Details

StatusFinished
Effective start/end date10/13/15 → 10/13/18

Funding

  • Nivalis Therapeutics, Inc. (Prot #N91115-2CF-05 (SNO-6))